Cerene Cryotherapy Device (Model number FGS-7000); Exhaust Collection Bag (Model number FGS-8000); Exhaust Collection Ba
Channel Medsystems, Inc. · Decision date Nov 3, 2026
What did the FDA approve?
The FDA recorded an approval decision dated 2026-11-03 for PMA supplement P180032/S025, submitted by Channel Medsystems, Inc. The supplement is classified as a Real-Time Process review with a stated reason of Change Design/Components/Specifications/Material. The listed title covers the Cerene Cryotherapy Device (model FGS-7000) together with Exhaust Collection Bag components (model FGS-8000 and a further truncated entry).
The recorded statement limits the action to approval of minor design changes to the Exhaust Collection Bag. This is a supplement-level decision, not a new approval of the Cerene Cryotherapy Device as a whole. The source does not describe the specific design changes, their technical rationale, or any supporting data, and it does not state clinical implications; those details would reside in the supplement review documents, which were not provided.
The device category is thermal ablation, endometrial, with product code MNB and specialty Obstetrics/Gynecology. The source gives no information on labeling changes, postmarket requirements, or effective date beyond the recorded decision date.
FDA approval order statement
Approval for minor design changes to the Exhaust Collection Bag.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Nov 3, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P180032/S025
- Regulatory pathway
- PMA supplement
- Applicant
- Channel Medsystems, Inc.
- Product code
- MNB
- Decision code
- APPR
- Decision date
- Nov 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, thermal ablation, endometrial.
- Applicant
- Channel Medsystems, Inc.
- Product code
- MNB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P180032. Subsequent supplements may change the device or its indications.
FDA decision timeline
P180032 · Original PMA
Cerene Cryotherapy Device
P180032/S024 · Related supplement
Cerene Cryotherapy Device
P180032/S025 received
Application receipt date recorded by FDA.
P180032/S025 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P180032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Cerene Cryotherapy DeviceP180032 | Channel Medsystems, Inc. | PMA approval | Mar 28, 2019 | FDA |
Cerene Cryotherapy DeviceP180032/S024 | Channel Medsystems, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Explore the linked device profile
Other records with product code MNB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MINERVA ENDOMETRIAL ABLATION SYSTEMP140013/S019 | Axora Medical, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| Axora Medical, Inc. | PMA approval | Jul 27, 2015 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Channel Medsystems, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5858 Horton St., Suite 200, Emeryville, CA, 94608
Sources and methodology
- Original FDA record: P180032/S025
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


